文献速递传染病防控与疫情报告免疫规划

重组亚单位疫苗保护豚鼠抵抗致死性埃博拉病毒感染

Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.
PubMed 文献 · Vaccine · 2019-07-16

埃博拉病毒 outbreaks 病死率可达90%,西非疫情感染近30000人、死亡超11000人。研究开发昆虫细胞来源的佐剂化蛋白疫苗,含EBOV糖蛋白联合或不联合VP24、VP40,配三种佐剂之一,在豚鼠中评估免疫原性与攻毒保护。结果显示候选疫苗诱导高滴度抗原特异性抗体,其中两种提供完全或近完全保护,部分保护组存在雄性死亡、雌性存活的性别偏倚。

要点

  • 昆虫细胞来源佐剂化亚单位疫苗在豚鼠中安全且免疫原性强。
  • 含EBOV糖蛋白的候选疫苗中两种对致死性攻毒提供完全或近完全保护。
  • 部分保护组出现性别偏倚:雄性豚鼠死亡而雌性存活。

核心结论

  • 研究开发的安全且免疫原性佐剂亚单位疫苗在豚鼠中均匀保护抵抗埃博拉病毒病。
  • 两种候选疫苗对致死性EBOV攻毒提供完全或近完全保护。

研究设计与样本

  • 在豚鼠中测试含EBOV糖蛋白联合或不联合基质蛋白VP24和VP40、配三种不同佐剂之一的候选疫苗的免疫原性与对致死性EBOV攻毒的保护效力。

主要发现

  • 候选疫苗在免疫动物中诱导高滴度抗原特异性抗体。
  • 两种候选疫苗提供完全或近完全保护抵抗致死性攻毒。
  • 部分保护免疫组存在性别偏倚,雄性豚鼠死于疾病而雌性存活。

临床怎么用

  • 昆虫细胞来源佐剂化亚单位疫苗可作为安全且免疫原性的EBOV候选疫苗进一步开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ebola virus (EBOV) is among the deadliest pathogens known to man causing infrequent outbreaks of hemorrhagic disease. In humans, the case fatality rates in the outbreaks can reach 90%. During the West African epidemic almost 30,000 people were infected and of these over 11,000 fatalities were reported. Currently, we are facing an uncontained larger outbreak in the Democratic Republic of the Congo. Even though EBOV was discovered in 1976, extensive efforts to develop countermeasures, particularly therapeutics and vaccines, started late and there is still no FDA-approved product available. Nevertheless, one candidate vaccine, the rVSV-ZEBOV, is being used in clinical trials during the current outbreak with the hope of ending the human transmission chains. However, adverse reactions to administration of some EBOV vaccines have been reported; therefore, we have developed a safe and efficacious formulation of insect-cell derived adjuvanted protein vaccines. Vaccine candidates containing the EBOV glycoprotein with or without matrix proteins VP24 and VP40 formulated with one of three different adjuvants were tested in guinea pigs for immunogenicity and efficacy against lethal EBOV challenge. The results demonstrated that these vaccine candidates engendered high titers of antigen-specific antibodies in immunized animals and two of these vaccine candidates afforded complete or nearly complete protection against lethal challenge. Interestingly, we found a sex bias in partially protected immunized groups with male guinea pigs succumbing to disease and females surviving. In summary, we developed a safe and immunogenic adjuvanted subunit vaccine uniformly protective against EBOV disease in guinea pigs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lehrer AT, Wong TS, Lieberman MM, et al. Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. Vaccine. 2019. PMID: 31324500. doi:10.1016/j.vaccine.2019.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。